MALARIA ELIMINATION THROUGH ASYMPTOMATIC DIAGNOSIS
THE CASE FOR MALARIA ERADICATION
Damaged Public Health
Malaria is an infectious disease of the most vulnerable that affected
229 million people
were children under the age of five
Malaria is among
the reasons for
lost economic growth
, particularly for low-income countries.
the annual lost GDP caused by malaria in Africa
also the number for
the global annual direct costs of malaria,
including illness, treatment and premature deaths
THE CASE FOR ASYMPTOMATIC DIAGNOSIS
current malaria diagnostic
technologies on the market
Malaria Rapid Diagnostic Tests (RDTs)
are not designed to detect asymptomatic carriers.
the World Health Organization currently cannot provide policy and guidance on asymptomatic screening in their global strategy on malaria eradication, leaving the global market for asymptomatic malaria diagnostics unaddressed.
Asymptomatic patients are one of our main concerns right now because a good proportion of the latest outbreaks we've seen are initiated by asymptomatic patients. The rest is imported cases, but if at least we could better diagnose them it will be a game changer.
Manuel Garcia, M.D.
GAD Associate CHAI (Clinton Health Access Initiative) / Malaria Access Program Mesoamerica
HOW OUR CAMPAIGN WORKS
INCENTIVIZE & EDUCATE
Raise awareness of the importance of malaria asymptomatic screening and improve general health literacy within the local community in regard to malaria elimination through our collaboration with local health organizations.
Technical training for local health practitioners on the use of our novel malaria diagnostic toolkit.
All asymptomatic diagnoses will be done using VivaKit - Hemolytics' novel malaria diagnostic toolkit - with a dual approach: active case detection (ACD) and reactive case detection (RACD).
TREATMENT & DATA COLLECTION
Detected asymptomatic carriers of the malaria parasites will be treated accordingly.
Data will be collected to evaluate the impact of asymptomatic screening in eliminating malaria.
Hemolytics is a medtech start-up based in the bilingual city of Fribourg, Switzerland. Originally a research project at the Adolphe Merkle Institute at the University of Fribourg, Hemolytics has grown into an impact-driven spin-off with a pre-founding team that is currently planning for Hemolytics' foundation at the end of summer 2021. The company's mission is to bring Hemolytics' life-saving technology to as many underserved communities as possible.
We aim to demonstrate the importance of asymptomatic screening in the arsenal of tools to fight malaria, which will help the World Health Organization to officially endorse asymptomatic screening in their global strategy or malaria eradication. This will allow the creation of supporting policy and guidance for us as well as other innovators that share the mutual goal of removing this ancient disease from our world once and for all.
We are a multidisciplinary team of five changemakers who are inspired to create a lasting social impact through knowledge-based innovation and entrepreneurship (click on the images for more details).
Behind the pre-founding team is our board of advisors, who have been guiding us with their scientific insight, industry experience, and more importantly, a strong belief in Hemolytics and its mission (click on the images for more details).
OUR MILESTONES (HIGHLIGHTS)
19th May: Patent application
Seed round funding
September: Incorporate Hemolytics SA